GIM
BMRN icon

Granahan Investment Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Granahan Investment Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-556,200
Closed -$40.1M – 212
2013
Q3 		$40.1M Sell
556,200
-44,200
-7% -$2.94M 1.07% 18
2013
Q2 		$33.5M Buy
+600,400
New +$37.4M 0.96% 24

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Granahan Investment Management's BMRN Position: Q4 2013 in Review

Granahan Investment Management sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2013, closing a stake of 556,200 shares — an estimated $40.1M sold.

Granahan Investment Management first reported a position in BMRN in Q2 2013 and held it in 2 quarters. The position peaked at $40.1M in Q3 2013. 306 funds tracked by Wall St. Rank hold BMRN as of Q4 2013.

  • Granahan Investment Management reported no remaining BioMarin Pharmaceuticals position as of Q4 2013 after selling out during the quarter.
  • Granahan Investment Management sold 556,200 BioMarin Pharmaceuticals shares in Q4 2013, an estimated $40.1M.
  • Granahan Investment Management first reported a position in BioMarin Pharmaceuticals in Q2 2013 and held it in 2 quarters.
  • Granahan Investment Management's BioMarin Pharmaceuticals position peaked at $40.1M in Q3 2013.
  • 306 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2013.

Based on Granahan Investment Management's 13F filing for Q4 2013, filed 30 Jan 2014.